
multiQure is a life sciences company developing therapies for rare genetic neurodegenerative disorders, and its portfolio comprises RNAi gene therapy.
multiqure.comCrawled Nov 11, 2026
Pure Biologics develops next-generation antibodies for immunotherapy, targeting tumor cells or immune suppression in the tumor microenvironment.
For several years, we have participated in various scientific research projects, building collaborative international R&D consortia. During this time, we have contributed our expertise and technological platforms by providing antibodies, aptamers, recombinant proteins and other solutions.
Pure Biologics develops immuno-oncology drugs and non-systemic therapies for autoimmune, neurological, and rare diseases, focusing on active biological molecules.
multiQure’s team includes employees with broad expertise gained in global research units.
multiQure’s foundation is a group of highly skilled and energetic people with diverse competencies and experience in Polish and international institutions.
multiQure employs a diverse, multidisciplinary team with experience in domestic and international institutions.
Pure Biologics focuses on biological drug discovery and development in immuno-oncology using its own technology platform for selecting active molecules.
Pure Biologics aims to develop its research portfolio, scientific and business competencies, infrastructure, and partnerships with biotech and pharmaceutical companies.
The history of multiQure spans almost fifteen years of work by a team of scientists on gene therapy for Huntington's disease and other polyglutamine diseases – severe, incurable neurodegenerative disorders that affect more than 100,000 people worldwide today.
Pure Biologics specializes in research and development of innovative biological drugs, ex vivo therapies, and diagnostics using PureSelect2 and PureApta platforms.
multiQure publishes and presents scientific achievements in journals, monographs, and global conferences to evaluate results and foster development.
multiQure’s therapeutic portfolio includes RNAi gene therapy for Huntington’s disease and other polyglutamine diseases, aiming to halt disease progression.
multiQure reports high demand for collaboration discussions, with **15 one-on-one partnering meetings already booked** two weeks before BIO-Europe 2026. The biotech company leverages such engagements to explore potential alliances in drug development or licensing. Industry interest reflects growing momentum for its pipeline projects ahead of the major biotech conference.
Curium acquires Lantheus in an up-to-$8.0B deal, with valuation partly tied to royalty and sublicense income. KKR acquires Integer for $5.7B, while Supernus buys Indivior for $2.2B. Smaller deals include Tarsus acquiring Alkeus for $450M, with potential earn-outs up to $800M. AstraZeneca and Bristol Myers Squibb merger talks, initially reported near $400B, were denied by a senior source.
MultiQure S.A. reports a net loss of **PLN 9.82 million** for 2025, an improvement from the **PLN 19.44 million** loss in 2024. Basic loss per share from continuing operations also decreased to **PLN 1.59**, down from **PLN 3.78** the prior year. The company provides no further details on revenue, operational changes, or pipeline updates in the earnings release.
Pure Biologics S.A. reports a net loss of **PLN 1.34 million** for Q1 2025, an improvement from the **PLN 4.97 million** loss in the same period a year prior. Basic loss per share also narrows to **PLN 0.34** from **PLN 1.49** annually. The company continues to operate in a loss-making phase while showing reduced financial strain.
Pure Biologics S.A. reports a net loss of **PLN 19.44 million** for 2024, an improvement from the **PLN 35.69 million** loss recorded in 2023. The company’s basic loss per share from continuing operations widens to **PLN 3.78**, up from **PLN 3.18** the prior year. Financial results reflect ongoing operational challenges amid potential development in its biologics pipeline.